Yeast Polysaccharide Affects Fusaric Acid Content in Maize Root Rot

Yeast-Derived Products: The Role of Hydrolyzed Yeast and Yeast Culture in Poultry Nutrition—A Review

Simple Summary

Yeast and yeast-derived products are largely employed in animal nutrition to support animals’ health and to improve their performance. Thanks to their components, including mannans, β-glucans, nucleotides, vitamins, and other compounds, yeasts have numerous beneficial effects. Among yeast-derived products, hydrolyzed yeasts and yeast cultures have received less attention, but, although the results are somewhat conflicting, in most of the cases, the available literature shows improved performance and health in poultry. Thus, the aim of this review is to provide an overview of hydrolyzed-yeast and yeast-culture employment in poultry nutrition, exploring their effects on the production performance, immune response, oxidative status, gut health, and nutrient digestibility. A brief description of the main yeast bioactive compounds is also provided.

Abstract

Yeasts are single-cell eukaryotic microorganisms that are largely employed in animal nutrition for their beneficial effects, which are owed to their cellular components and bioactive compounds, among which are mannans, β-glucans, nucleotides, mannan oligosaccharides, and others. While the employment of live yeast cells as probiotics in poultry nutrition has already been largely reviewed, less information is available on yeast-derived products, such as hydrolyzed yeast (HY) and yeast culture (YC). The aim of this review is to provide the reader with an overview of the available body of literature on HY and YC and their effects on poultry. A brief description of the main components of the yeast cell that is considered to be responsible for the beneficial effects on animals’ health is also provided. HY and YC appear to have beneficial effects on the poultry growth and production performance, as well as on the immune response and gut health. Most of the beneficial effects of HY and YC have been attributed to their ability to modulate the gut microbiota, stimulating the growth of beneficial bacteria and reducing pathogen colonization. However, there are still many areas to be investigated to better understand and disentangle the effects and mechanisms of action of HY and YC.

Live yeast and yeast extracts with and without pharmacological levels of zinc on nursery pig growth performance and antimicrobial susceptibilities of fecal Escherichia coli

A total of 360 weanling barrows (Line 200 ×400, DNA, Columbus NE; initially 5.6 ± 0.03 kg) were used in a 42-d study to evaluate yeast-based pre- and probiotics (Phileo by Lesaffre, Milwaukee, WI) in diets with or without pharmacological levels of Zn on growth performance and antimicrobial resistance (AMR) patterns of fecal Escherichia coli. Pens were assigned to 1 of 4 dietary treatments with 5 pigs per pen and 18 pens per treatment. Dietary treatments were arranged in a 2 × 2 factorial with main effects of yeast-based pre- and probiotics (none vs. 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% NucleoSaf from d 0 to 7, then concentrations were lowered by 50% from d 7 to 21) and pharmacological levels of Zn (110 vs. 3,000 mg/kg from d 0 to 7, and 2,000 mg/kg from d 7 to 21 with added Zn provided by ZnO). All pigs were fed a common diet from d 21 to 42 post-weaning. There were no yeast ×Zn interactions or effects from yeast additives observed on any response criteria. From d 0 to 21, and 0 to 42, pigs fed pharmacological levels of Zn had increased (P < 0.001) ADG and ADFI. Fecal samples were collected on d 4, 21, and 42 from the same three pigs per pen for fecal dry matter (DM) and AMR patterns of E. coli. On d 4, pigs fed pharmacological levels of Zn had greater fecal DM (P = 0.043); however, no differences were observed on d 21 or 42. E. coli was isolated from fecal samples and the microbroth dilution method was used to determine the minimal inhibitory concentrations (MIC) of E. coli isolates to 14 different antimicrobials. Isolates were categorized as either susceptible, intermediate, or resistant based on Clinical and Laboratory Standards Institute (CLSI) guidelines. The addition of pharmacological levels of Zn had a tendency (P = 0.051) to increase the MIC values of ciprofloxacin; however, these MIC values were still well under the CLSI classified resistant breakpoint for Ciprofloxacin. There was no evidence for differences (P > 0.10) for yeast additives or Zn for AMR of fecal E. coli isolates to any of the remaining antibiotics. In conclusion, pharmacological levels of Zn improved ADG, ADFI, and all isolates were classified as susceptible to ciprofloxacin although the MIC of fecal E. coli tended to be increased. Thus, the short-term use of pharmacological levels of Zn did not increase antimicrobial resistance. There was no response observed from live yeast and yeast extracts for any of the growth, fecal DM, or AMR of fecal E. coli criteria.